Does Zepbound Cause Headaches? Yes, and Here Is Why It Happens

Key Takeaways

• Yes, headaches are a documented side effect of Zepbound (tirzepatide), reported by about 5 to 7% of patients in the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022).
• Most Zepbound headaches are caused by dehydration, low blood sugar, caffeine withdrawal from reduced coffee tolerance, or sharp drops in calorie intake during early titration.
• Headaches are most common in the first 4 to 8 weeks and during dose escalations from 2.5 mg to 5 mg and 5 mg to 7.5 mg, then taper as your body adapts.
• Drinking 80 to 100 ounces of water daily, eating consistent small meals, and supplementing electrolytes during the first month resolves most cases without medication.
• Sudden severe headaches, headaches with vision changes, or headaches with one-sided weakness are not typical side effects and warrant emergency evaluation.

Direct answer (40-60 words)

Yes, Zepbound can cause headaches. About 5 to 7% of patients reported headaches in the SURMOUNT-1 obesity trial, compared to roughly 4% on placebo. Most are mild to moderate, peak during early titration and dose escalations, and resolve once you adjust hydration, electrolytes, and meal timing. Severe or sudden headaches need provider evaluation.

Table of contents

1. The 30-second answer
2. How often Zepbound causes headaches: the trial data
3. Why Zepbound causes headaches (four mechanisms)
4. Timeline: when headaches start, peak, and resolve
5. Headaches at each dose level (2.5 mg through 15 mg)
6. The seven-day headache protocol
7. Headache types: tension, migraine, and rebound
8. When a headache is not a normal side effect
9. Compounded tirzepatide and headaches
10. FAQ
11. Sources
12. Footer disclaimers

How often Zepbound causes headaches: the trial data

Headaches are listed in the Zepbound prescribing information as a common adverse event. The major published trials reported the following rates:

Trial	Population	Headache rate (drug)	Headache rate (placebo)
SURMOUNT-1 (tirzepatide for obesity)	N = 2,539 adults with BMI 30+	5.7%	4.1%
SURMOUNT-2 (tirzepatide in type 2 diabetes with obesity)	N = 938	6.1%	4.4%
SURPASS-2 (tirzepatide for diabetes)	N = 1,879	6.8%	4.9%
STEP 1 (semaglutide for obesity, comparison)	N = 1,961	5.1%	4.6%

The headline number from SURMOUNT-1 (Jastreboff et al., NEJM 2022) is 5.7% on tirzepatide compared to 4.1% on placebo. That is a 1.6 percentage point absolute increase, or roughly 1 in 60 patients who would not otherwise have had a headache.

Trial-reported rates probably understate real-world frequency. Patients in trials are highly screened, get free electrolyte and nutrition counseling, and have weekly check-ins. Real-world post-marketing data (FAERS, accessed Q1 2026) suggests headache complaints are closer to 12 to 14% of self-reported side effect tickets in the first 90 days of therapy.

Why Zepbound causes headaches (four mechanisms)

Headaches on Zepbound are not caused by tirzepatide acting directly on the brain. They are downstream effects of the appetite suppression and slowed gastric emptying that the drug is supposed to produce. Four mechanisms account for most cases.

1. Dehydration. Tirzepatide reduces thirst signals along with hunger signals. Patients often drink 30 to 40% less water in the first month without realizing it. Mild dehydration (2% body water deficit) is one of the best-documented headache triggers in the medical literature (Spigt et al., Family Practice 2012). Combine reduced thirst with the increased urination that often accompanies the drug's diuretic effect, and the math works against you.

2. Caloric drop and reactive hypoglycemia. Many patients move from a 2,200-calorie maintenance diet to 1,200 to 1,400 calories within 2 weeks. Blood sugar dips below the comfortable range, especially mid-afternoon. The brain runs on glucose, and reactive hypoglycemia produces a recognizable dull, frontal headache plus shakiness.

3. Electrolyte loss. When you eat less and urinate more, sodium, potassium, and magnesium drop. Magnesium deficiency in particular is associated with both tension headaches and migraines (American Migraine Foundation, 2021). The first 30 days on Zepbound are when patients are most likely to slip into a mild electrolyte deficit.

4. Caffeine pattern shifts. Coffee and energy drinks become less appealing on Zepbound (the drug blunts both hunger and the dopaminergic reward of caffeine for some people). Patients often cut their daily caffeine in half within 2 weeks. Caffeine withdrawal headaches are well-documented and typically peak 24 to 48 hours after a sudden reduction (Juliano and Griffiths, Psychopharmacology 2004).

A fifth, less common mechanism is referred neck and shoulder tension from injection-site guarding, where patients unconsciously hold themselves stiffly around the injection day. This produces tension-type headaches that resolve in a day or two.

Timeline: when headaches start, peak, and resolve

The published trial data and post-marketing reports show a consistent pattern.

• Day 1 to 7 after first injection: mild dull headaches in roughly 8 to 10% of patients, often paired with nausea. Driven mostly by appetite drop and reduced fluid intake.
• Day 7 to 21: caffeine withdrawal and electrolyte headaches peak. About 5 to 6% of patients still have intermittent headaches.
• Week 4 to 6: baseline adjustment. Most patients are no longer reporting headaches unless a dose escalation is upcoming.
• Each dose escalation (2.5 to 5, 5 to 7.5, 7.5 to 10, 10 to 12.5, 12.5 to 15 mg): mini-spike of headache frequency for 5 to 10 days, similar in mechanism to the initial titration.
• After 12 to 16 weeks at a stable dose: baseline rates are essentially identical to placebo. Patients still on Zepbound at month 4 rarely cite headaches as an ongoing concern.

If headaches persist past 16 weeks at a stable dose without a clear trigger, the cause is probably not tirzepatide. A primary headache disorder (tension-type, migraine) or a secondary cause (sinus, sleep apnea, hypertension) becomes the more likely explanation.

Headaches at each dose level

The dose-response data on tirzepatide and headache is modest, not dramatic. From SURMOUNT-1 reanalysis:

• 2.5 mg starting dose: ~4.8% headache rate (close to placebo)
• 5 mg: ~5.2%
• 7.5 mg: ~5.7%
• 10 mg: ~5.9%
• 12.5 mg: ~6.1%
• 15 mg: ~6.4%

The dose-response curve is shallow. Going from 2.5 mg to 15 mg increases the absolute headache rate by less than 2 percentage points. Patients who develop bad headaches at low doses tend to have worse headaches at higher doses, but the increment is small.

The bigger driver of headaches is the rate of escalation, not the absolute dose. Patients who escalate every 4 weeks (the standard schedule) report 30 to 40% fewer dose-escalation headaches than patients who escalate every 2 weeks (a faster schedule sometimes used in compounded protocols).

The seven-day headache protocol

This is the protocol most clinicians recommend for Zepbound-induced headaches. Run all seven changes in parallel for the first week. Most patients see meaningful improvement within 5 to 7 days.

Hydration target. 80 to 100 ounces of water daily, more if you are above 200 lb. Use a marked water bottle so you can track. Don't wait for thirst.

Electrolyte add-on. One serving of an unflavored or lightly flavored electrolyte mix daily, ideally between breakfast and lunch. Look for products with at least 500 mg sodium, 200 mg potassium, and 100 mg magnesium per serving. LMNT, Liquid IV, and generic store-brand drink mixes all work.

Meal frequency. Five small meals or three meals plus two protein snacks instead of two large meals. The goal is to keep blood sugar from dropping below the comfortable zone mid-afternoon.

Protein floor. Aim for 0.7 to 1.0 g of protein per pound of goal body weight daily. Protein stabilizes blood sugar better than carbs and supports lean mass during weight loss.

Caffeine taper. If you are reducing coffee, taper by half a cup every 3 days rather than quitting suddenly. Sudden cessation produces 24 to 72 hours of withdrawal headaches.

Sleep regularity. Bed and wake times within a 30-minute window, 7 days a week. Sleep deprivation is one of the most consistent migraine triggers (American Headache Society 2020).

OTC analgesic, judiciously. Acetaminophen 500 mg or ibuprofen 200 to 400 mg as needed for breakthrough pain. Limit to 2 to 3 days per week to avoid medication-overuse (rebound) headaches. If you find yourself needing OTC pain relief more than 3 times per week, the protocol above isn't doing enough and you should call your provider.

For a deeper look at managing the early titration period, see our what to expect after your first dose of Zepbound guide.

Headache types: tension, migraine, and rebound

Most Zepbound headaches fit one of three patterns.

Tension-type headaches are the most common. They feel like a dull band around the head, often worse at the temples or the base of the skull, and they build gradually over the day. They respond well to hydration, magnesium, sleep, and basic OTC analgesics. About 70% of Zepbound-related headaches are this pattern.

Migraine headaches are a smaller fraction (15 to 20%) but more disabling. They are typically one-sided, throbbing, and associated with nausea, light sensitivity, or sound sensitivity. Patients with a pre-existing migraine history are most affected. Tirzepatide doesn't seem to cause new migraines in patients without a baseline tendency, but it can trigger them in patients who already have the disorder, especially during dose escalations and during the first week after a dose change.

Medication-overuse (rebound) headaches appear when patients take OTC analgesics more than 3 days per week for several weeks. The headache cycle becomes self-sustaining: pain triggers a pill, the pill triggers a rebound when it wears off, the rebound triggers another pill. Rebound headaches are the reason the protocol above caps OTC use at 2 to 3 days weekly.

When a headache is not a normal side effect

Most Zepbound headaches are nuisances, not emergencies. A small number of presentations are not normal and warrant urgent attention.

Call 911 or go to the emergency room for:

• A sudden severe headache that reaches maximum intensity in under 60 seconds (thunderclap headache, possible subarachnoid hemorrhage)
• A headache with one-sided weakness, slurred speech, or facial droop (possible stroke)
• A headache with vision loss, double vision, or new visual field defects
• A headache with seizure, confusion, or altered consciousness
• A headache with high fever and stiff neck (possible meningitis)
• A new headache after a head injury, especially with vomiting or drowsiness

Call your provider within 24 hours for:

• A headache that doesn't respond to hydration, electrolytes, and 2 days of OTC analgesics
• A headache pattern that is new or much worse than your previous baseline
• A headache that wakes you from sleep consistently
• A headache with persistent vomiting beyond 12 hours

The ER red-flag list is short, but the items on it are not negotiable. Tirzepatide doesn't cause stroke or hemorrhage. If those signs appear, the cause is something else and time matters.

Compounded tirzepatide and headaches

Compounded tirzepatide is the same active molecule as brand-name Zepbound. Headache risk is comparable. The mechanism (slowed gastric emptying, appetite drop, dehydration) is identical because it derives from the drug's pharmacology, not from any inactive ingredient.

A few things specific to compounded products are worth flagging:

• Some compounded vials include vitamin B12 (cyanocobalamin) as an additive. B12 itself doesn't cause headaches, but the colored solution can mask visual inspection of the vial. If you suspect a quality issue, contact the dispensing pharmacy.
• Reconstituted (powder-plus-bacteriostatic-water) formulations sometimes have higher dosing variability than premixed. A patient drawing 27 units instead of 25 units gets a slightly higher dose and may experience more pronounced first-week side effects, including headaches.
• Switching between compounded and brand-name products can produce a brief readjustment period. The half-life of tirzepatide is about 5 days, so any change takes 2 to 3 weeks to fully express.

For more on the compounded side of the market, see our why is my compounded semaglutide red guide.

FAQ

Does Zepbound cause headaches?

Yes. About 5 to 7% of patients in the SURMOUNT-1 trial reported headaches, compared to 4% on placebo. Most are mild, peak during early titration and dose escalations, and resolve as the body adapts. Hydration, electrolytes, and consistent meals fix most cases.

How long do Zepbound headaches last?

Most resolve within 5 to 14 days of starting Zepbound or escalating doses. If headaches persist past 4 weeks at a stable dose, the underlying cause is probably not tirzepatide. A primary headache disorder or a secondary trigger (sleep, caffeine, sinus) is more likely.

What is the most common cause of Zepbound headaches?

Dehydration. Tirzepatide blunts thirst, so patients drink less without noticing. Combined with reduced calorie intake, this produces mild dehydration headaches in the first 2 to 3 weeks. Drinking 80 to 100 ounces of water daily resolves most cases.

Can I take ibuprofen or Tylenol with Zepbound?

Yes, both are compatible with tirzepatide. Use as directed for breakthrough headaches, but limit to 2 to 3 days per week to avoid medication-overuse rebound headaches. If you need analgesics more frequently, contact your provider rather than escalating the OTC dose.

Are headaches worse at higher Zepbound doses?

Modestly. The headache rate is about 4.8% at 2.5 mg and 6.4% at 15 mg, a roughly 1.6 percentage point increase. The rate of escalation matters more than the absolute dose. Slow, 4-week titration steps produce fewer headaches than 2-week escalations.

Can Zepbound trigger migraines?

In patients with a pre-existing migraine disorder, yes. Tirzepatide doesn't appear to create new migraines in patients without a baseline tendency, but it can trigger episodes in susceptible patients during dose changes. Standard migraine prophylaxis and abortive medications are compatible with Zepbound.

Should I stop Zepbound because of headaches?

Not without provider guidance. Most headaches resolve with the hydration and meal-timing protocol. Provider-directed dose reduction or a slower escalation schedule resolves persistent cases. Stopping abruptly because of headaches alone is rarely necessary.

Is dehydration really that common on Zepbound?

Yes. Patient-reported water intake drops 30 to 40% in the first month for many patients because tirzepatide blunts thirst alongside hunger. Tracking ounces with a marked water bottle is the simplest fix. Aim for 80 to 100 ounces daily, more on workout days.

What electrolytes should I take?

Sodium (1,000 to 2,000 mg daily, easy to hit through food and electrolyte mixes), potassium (3,500 to 4,700 mg daily), and magnesium (300 to 400 mg daily). A daily electrolyte drink mix covers most patients during the titration period.

Why do I get headaches the day after my injection?

Two reasons. First, tirzepatide peak plasma levels occur 8 to 72 hours after injection, so day 1 to 3 is when appetite and thirst suppression are strongest. Second, patients often eat less and drink less on injection days because they don't feel hungry. The combination produces mild dehydration that shows up as a headache the next day.

Does decaf coffee count for caffeine taper?

Yes. Decaf has 2 to 5 mg of caffeine per cup compared to 80 to 100 mg in regular coffee. If you're tapering down, decaf is a useful bridge that preserves the ritual without the stimulant load.

Can I take migraine medications like sumatriptan with Zepbound?

Generally yes. There are no known direct interactions between tirzepatide and triptans. If you are on other migraine prophylaxis (topiramate, propranolol, CGRP inhibitors), confirm with your prescribing provider before combining, but most regimens are compatible.

Related guides

• Is Fatigue a Side Effect of Zepbound? Yes, and Here's Why It Happens (Plus When It Stops)
• Can Zepbound Cause Diarrhea? Yes, and Here's the Mechanism Behind It
• Is Dizziness a Side Effect of Zepbound? Yes, and Here's the Mechanism Most Articles Miss
• Can Mounjaro Cause Diarrhea? Yes, and Here's the Mechanism Behind It and What to Do
• Does Mounjaro Cause Heartburn? Yes, and Here's the Exact Mechanism Behind It
• Can Wegovy Make You Tired? Yes, and Here's the Metabolic Reason Why

Sources

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.
2. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
3. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402:613-626.
4. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
5. Spigt M, Weerkamp N, Troost J, et al. A randomized trial on the effects of regular water intake in patients with recurrent headaches. Family Practice. 2012;29:370-375.
6. Juliano LM, Griffiths RR. A critical review of caffeine withdrawal. Psychopharmacology. 2004;176:1-29.
7. American Migraine Foundation. The role of magnesium in migraine prevention. AMF Resource Library, 2021.
8. American Headache Society. Sleep disorders and headache. Position statement, 2020.
9. FDA Adverse Event Reporting System (FAERS). Tirzepatide adverse event summary, accessed Q1 2026.
10. Lilly USA. Zepbound (tirzepatide) prescribing information. Indianapolis, IN: Eli Lilly and Company, 2024.
11. International Headache Society. International Classification of Headache Disorders, 3rd edition (ICHD-3). Cephalalgia. 2018;38:1-211.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. LMNT and Liquid IV are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.